Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,461
datasets available to search
ShareScore release 0.9.0
Dataset results
2,461 results for “Rheumatoid arthritis”
Data from: MFAP5 contributes to inflammation, synovial hyperplasia and joint damage in rheumatoid arthritis via integrin-ERK signaling
<p>Synovial hyperplasia is the primary pathological changes of RA and FLS is the principal etiological cellular component that drives and constitutes the pathological lesions. To elucidate the molecular mechanism of how FLS may contribute to RA, we performed transcriptome profiling to determine the DEGs between normal and RA FLS. We compared the primary FLS isolated from healthy control (HFLS) to that isolated from RA patients (RA FLS), and also to an immortalized RA FLS cell line MH7A immortalized by stably transfecting primary RA FLS cells with SV40 T antigen gene. </p>
Fig. 3 in Sesquiterpenes from Kadsura coccinea attenuate rheumatoid arthritis-related inflammation by inhibiting the NF-κB and JAK2/STAT3 signal pathways
Fig. 3. Key ROESY correlations of compounds 1and 2.
Fig. 1 in Sesquiterpenes from Kadsura coccinea attenuate rheumatoid arthritis-related inflammation by inhibiting the NF-κB and JAK2/STAT3 signal pathways
Fig. 1. Structures of compounds 1–20 from K. coccinea.
Fig. 2. Key 1H–1H in Sesquiterpenes from Kadsura coccinea attenuate rheumatoid arthritis-related inflammation by inhibiting the NF-κB and JAK2/STAT3 signal pathways
Fig. 2. Key 1H–1H COSY and HMBC correlations of compounds 1and 2.
Predictive risk factors before the onset of familial rheumatoid arthritis: the Tatarstan cohort study
<p>Dataset for: https://www.frontiersin.org/articles/10.3389/fmed.2023.1227786/abstract</p> <p> </p> <p>Predictive risk factors before the onset of familial rheumatoid arthritis: the Tatarstan cohort study</p> <p> </p> <p>Background: A familial history of rheumatoid arthritis (RA) predisposes an individual for developing RA. This study aimed at investigating factors associated with this conversion from the Tatarstan cohort.Methods: 144 individuals, referred to as pre-RA and at risk for familial RA, were selected 2 years (range: 2 to 21 years) before conversion to RA and compared to non-converted 328 first degree relatives (FDR) from RA as assessed after ≥ 2 years follow-up, and 355 healthy controls (HC). Preclinical parameters, and socio-demographic/individual/HLA genetic factors were analyzed when data were available at the time of enrolment.Results: As compared to FDR and HC groups, pre-RA individuals were characterized before conversion to RA by the presence of arthralgia, severe morning symptoms, a lower educational level, and rural location. An association with the HLA-DRB1 SE risk factor was also retrieved with symmetrical arthralgia and passive smoking. On the contrary, alcohol consumption and childless in women were protective and associated with the HLA-DRB1*07:01 locus.Conclusion: Before RA onset, a combination of individual and genetic factors characterized those who are at risk of progressing to RA among those with familial RA relatives.</p>
Randomised Double-Blind, Placebo-Controlled, Parallel Group Study in Patients With Active Rheumatoid Arthritis:Magnetic Resonance Imaging Sub-Study
ClinicalTrials.gov study NCT02092961. IPD Sharing: Not stated. Countries: 11. Publications: 0.
Efficacy and Safety of CDP870 Versus Placebo in the Treatment of the Signs and Symptoms of Rheumatoid Arthritis
ClinicalTrials.gov study NCT00548834. IPD Sharing: Not stated. Countries: 0. Publications: 1.
Study to Assess the Efficacy and Safety of Rituximab in Patients With Rheumatoid Arthritis
ClinicalTrials.gov study NCT00074438. IPD Sharing: Not stated. Countries: 0. Publications: 1.
A Study on The Safety of Administering Rituximab at A More Rapid Rate in Patients With Rheumatoid Arthritis
ClinicalTrials.gov study NCT01382940. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Study of LY2439821 in Rheumatoid Arthritis
ClinicalTrials.gov study NCT01236118. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Factors of ILD in Newly Diagnosed Rheumatoid Arthritis
ClinicalTrials.gov study NCT04002765. IPD Sharing: NO. Countries: 1. Publications: 0.
Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α Blockers
ClinicalTrials.gov study NCT01217814. IPD Sharing: Not stated. Countries: 6. Publications: 0.
A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Non-biologic DMARDs
ClinicalTrials.gov study NCT01353859. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Brodalumab (AMG 827) in Rheumatoid Arthritis (RA) Participants With Inadequate Response to Methotrexate
ClinicalTrials.gov study NCT00950989. IPD Sharing: Not stated. Countries: 0. Publications: 1.
Safety and Efficacy of ACZ885 in Adult Patients With Established Rheumatoid Arthritis
ClinicalTrials.gov study NCT00504595. IPD Sharing: Not stated. Countries: 4. Publications: 0.
Infliximab Plus Methotrexate for the Treatment of Rheumatoid Arthritis
ClinicalTrials.gov study NCT00269867. IPD Sharing: Not stated. Countries: 0. Publications: 2.
Efficacy and Safety of CDP870 and Methotrexate Compared to Methotrexate Alone in Subjects With Rheumatoid Arthritis
ClinicalTrials.gov study NCT00544154. IPD Sharing: Not stated. Countries: 0. Publications: 1.
Oral CF101 Tablets Treatment in Patients With Rheumatoid Arthritis
ClinicalTrials.gov study NCT01034306. IPD Sharing: Not stated. Countries: 2. Publications: 0.
Characteristics of Rheumatoid Arthritis Patients With Atlantoaxial Synovitis Detected by Plain X-ray and MRI
ClinicalTrials.gov study NCT02774070. IPD Sharing: UNDECIDED. Countries: 0. Publications: 2.
An Observational Study of the Impact of RoActemra/Actemra on Fatigue in Patients With Rheumatoid Arthritis (PEPS)
ClinicalTrials.gov study NCT01185522. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.